NINTEDANIB FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS - INITIAL CLINICAL EXPERIENCE IN A UK COHORT

被引：4
|
作者：
Fletcher, S. V. [1 ]
Jones, M. G. [1 ]
Renzoni, E. [2 ]
Parfrey, H. [3 ]
Hoyles, R. [4 ]
Spinks, K. [5 ]
Kokosi, M.
Kwok, A. [6 ]
Warburton, C. [6 ]
Titmuss, V. [5 ]
Maher, T. [2 ]
Chua, F. [2 ]
Wells, A. [2 ]
Richeldi, L. [1 ]
Spencer, L. G. [6 ]
机构：
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] Royal Brampton Hosp, ILD Unit, London, England
[3] Papworth Hosp, Cambridge CB3 8RE, England
[4] John Radcliffe Hosp, Oxford, England
[5] Queen Alexandra Hosp, Portsmouth, Hants, England
[6] Aintree Univ Hosp NHS Fdn Trust, Liverpool, Merseyside, England
来源：
THORAX | 2015年 / 70卷
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1136/thoraxjnl-2015-207770.146
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P9
引用
收藏
页码：A78 / A78
页数：1
相关论文
共 50 条
  • [1] Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
    Valenzuela, Claudia
    Molina, Maria
    Diaz Chantar, Fatima
    Alonso, Tamara
    Rodriguez Portal, Jose Antonio
    Rodriguez Nieto, Maria Jesus
    Laporta, Rosalia
    Jesus Linares, Maria
    Ancochea, Julio
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [2] Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
    Valenzuela, Claudia
    Molina, Maria Molina
    Portal, Jose Antonio Rodriguez
    Ortiz, Romero
    Cano, Esteban
    Nieto, Maria Jesus Rodriguez
    Laporta, Rosalia
    Ancochea, Julio
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [3] Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
    Fletcher, Sophie V.
    Jones, Mark G.
    Renzoni, Elizabeth A.
    Parfrey, Helen
    Hoyles, Rachel K.
    Spinks, Katherine
    Kokosi, Maria
    Kwok, Apollinaris
    Warburton, Chris
    Titmuss, Vanessa
    Thillai, Muhunthan
    Simler, Nicola
    Maher, Toby M.
    Brereton, Christopher J.
    Chua, Felix
    Wells, Athol U.
    Richeldi, Luca
    Spencer, Lisa G.
    ERJ OPEN RESEARCH, 2018, 4 (04)
  • [4] Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
    Mullerpattan, Jai B.
    Porwal, Sana H.
    Sarkar, Trina A.
    Wagh, Haresh D.
    Udwadia, Zarir F.
    LUNG INDIA, 2019, 36 (05) : 465 - +
  • [5] Nintedanib for the treatment of idiopathic pulmonary fibrosis
    Varone, Francesco
    Sgalla, Giacomo
    Iovene, Bruno
    Bruni, Teresa
    Richeldi, Luca
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (02) : 167 - 175
  • [6] Nintedanib in the treatment of idiopathic pulmonary fibrosis
    Mazzei, Mariano E.
    Richeldi, Luca
    Collard, Harold R.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 121 - 129
  • [7] Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres
    Toellner, H.
    Beswick, W.
    Crooks, M.
    Donaldson, C.
    Forrest, I.
    Hart, S.
    Leonard, C.
    Major, M.
    Simpson, A.
    Chaudhuri, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
    Mulholland, S. A.
    Al Jbour, K.
    Steer, H.
    Gutsche, M.
    Foley, N.
    Srivastava, R.
    Sharp, C.
    Adamali, H. I.
    Barratt, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [9] Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
    Sathiyamoorthy, Gayathri
    Sehgal, Sameep
    Ashton, Rendell W.
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (06) : 393 - 398
  • [10] Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
    Fukihara, Jun
    Kondoh, Yasuhiro
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (12) : 1247 - 1254
12345